(Q52278603)

28 April 2018

title

A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia (English)

1 reference

28 April 2018

0 references

1 reference

7

1 reference

28 April 2018

author name string

Basile VS

1

1 reference

28 April 2018

Ozdemir V

2

1 reference

28 April 2018

Masellis M

3

1 reference

28 April 2018

Walker ML

4

1 reference

28 April 2018

Meltzer HY

5

1 reference

28 April 2018

Lieberman JA

6

1 reference

28 April 2018

Alva G

8

1 reference

28 April 2018

Kalow W

9

1 reference

28 April 2018

Macciardi FM

10

1 reference

28 April 2018

Kennedy JL

11

1 reference

28 April 2018

language of work or name

English

0 references

publication date

1 July 2000

1 reference

28 April 2018

published in

Molecular Psychiatry

1 reference

28 April 2018

volume

5

1 reference

28 April 2018

issue

4

1 reference

28 April 2018

page(s)

410-417

1 reference

28 April 2018

Tardive dyskinesia: prevalence and risk factors, 1959 to 1979.

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Incidence and correlates of tardive dyskinesia in first episode of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Predictors of the course of tardive dyskinesia in patients receiving neuroleptics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Association of the MscI polymorphism of the dopamine D3 receptor gene with tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Paroxetine potentiates the central nervous system side effects of perphenazine: Contribution of cytochrome P4502D6 inhibition in vivo*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Interethnic variation of drug metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

The CYP2D6 genotype predicts the oral clearance of the neuroleptic agents perphenazine and zuclopenthixol

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Effects of smoking on fluphenazine clearance in psychiatric inpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Prevalence of smoking among psychiatric outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

The epidemiology of tobacco use, dependence, and cessation in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping*

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Determinants of interindividual variability and extent of CYP2D6 and CYP1A2 inhibition by paroxetine and fluvoxamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Theophylline metabolism: Variation and genetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Reflections from distant cuvettes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Enzyme induction in the cytochrome P-450 system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Hypothesis: a nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Cigarette smoking is associated with abnormal involuntary movements in the general male population--a study of men born in 1933.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

Familial tardive dyskinesia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

The expression of schizophrenia, affective disorder and vulnerability to tardive dyskinesia in an extensive pedigree

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Possible genetic factors underlying the pathophysiology of tardive dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Debrisoquine oxidation phenotype and neuroleptic-induced dystonic reactions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Polymorphic Drug Metabolism in Schizophrenic Patients With Tardive Dyskinesia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Antipsychotic drug-induced movement disorders in schizophrenics in relation to CYP2D6 genotype

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Clinical significance of the sparteine/debrisoquine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

The relationship between paroxetine and the sparteine oxidation polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Steady-state serum concentrations of the neuroleptic perphenazine in relation to CYP2D6 genetic polymorphism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Paroxetine Steady-State Plasma Concentration in Relation to CYP2D6 Genotype in Extensive Metabolizers

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Disposition of perphenazine is related to polymorphic debrisoquin hydroxylation in human beings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Cigarette smoking and chlorpromazine disposition and actions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

The influence of cigarette smoking on haloperidol pharmacokinetics

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Lower plasma levels of haloperidol in smoking than in nonsmoking schizophrenic patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Smoking and schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Fluvoxamine is a potent inhibitor of the metabolism of caffeine in vitro

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Phenacetin O-deethylation by human liver microsomes in vitro: inhibition by chemical probes, SSRI antidepressants, nefazodone and venlafaxine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Use of caffeine metabolite ratios to explore CYP1A2 and xanthine oxidase activities

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Hypothesis: Comparisons of inter- and intra-individual variations can substitute for twin studies in drug research

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

The science of pharmacological variability: an essay

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Paroxetine shifts imipramine metabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Genetic polymorphism in the 5'-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Assays for CYP1A2 by testing in vivo metabolism of caffeine in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4000736

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4000736

1 reference

28 April 2018

1 reference

28 April 2018